Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents

Table 2 Levels of sIL-2R, ALT, and HBV DNA in the sera of patients with chronic hepatitis B virus infection (mean ± SD)

	DAA-group	P/R-group	P value
PASI (T0), mean ± SD	11.6 ± 5.2	9.4 ± 3.5	-
PASI (T1), mean ± SD	5.2 ± 1.6	8.3 ± 4.5	< 0.005
Biological treatment shifts, n (%)	-	8 (25)	< 0.001
Topical treatments (T0), n (%)	27 (100)	32 (100)	-
Topical treatments (T1), n (%)	27 (100)	32 (100)	-
DLQI (T0), mean ± SD	13 ± 2.3	12 ± 3.1	-
DLQI (T1), mean ± SD	4.2 ± 2.3	11 ± 2.3	< 0.001
HCV treatment details, n (%)	Sofosbuvir + daclatasvir: 25 (92.6)	Pegylated interferon-2α + ribavirin	-
	Sofosbuvir + simeprevir + ribavirin: 1 (3.7)	32 (100)
	Sofosbuvir + ribavirin: 1 (3.7)
Laboratory tests, mean ± SD
T0
ALT	45.6 ± 16.5	43 ± 9.2	-
AST	54.6 ± 5.51	52.4 ± 12.5	-
GGT	42.0 ± 13.59	43.3 ± 14.6	-
T1
ALT	42.21 ± 12.4	43 ± 8.5	-
AST	51.3 ± 4.2	51.9 ± 8.9	-
GGT	40.8 ± 12.2	42.9 ± 14.1	-
Dropout HCV-treatment, n (%)	0/27 (0)	9/32 (28.1)	< 0.005
SVR, n (%)	27/27 (100)	12/32 (37.5)	< 0.005

Categorical variables are expressed as n (%), and compared by χ² or Fisher’s exact test. Numeric variables are expressed as median and SD, and compared by Mann–Whitney or Kruskall–Wallis tests. Statistical significance was considered as a P-value of < 0.05. DAA: New Direct-Acting Antiviral Agent; P/R: Pegylated interferon-2α plus ribavirin; PASI: Psoriasis Area Severity Index; T0: Baseline time (before starting the hepatitis C eradication treatment); T1: Six months after the end of hepatitis C eradication treatment; DLQI: Dermatology Quality of Life Index; HCV: Hepatitis C virus; SVR: Sustained virological response; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase.